Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07508488 for Central Centrifugal Cicatricial Alopecia, Frontal Fibrosing Alopecia is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Deucravacitinib in the Treatment of Cicatricial Alopecias Phase 2 20 Open-Label
Clinical Trial NCT07508488 is designed to study Treatment for Central Centrifugal Cicatricial Alopecia, Frontal Fibrosing Alopecia. This Phase 2 interventional study is not yet recruiting. Enrollment is planned to begin on April 1, 2026 until the study accrues 20 participants. Led by Icahn School of Medicine at Mount Sinai, this study is expected to complete by January 21, 2027. The latest data from ClinicalTrials.gov was last updated on April 2, 2026.
Brief Summary
This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with ...Show More
Official Title
Deucravacitinib in the Treatment of Cicatricial Alopecias
Conditions
Central Centrifugal Cicatricial AlopeciaFrontal Fibrosing AlopeciaOther Study IDs
- STUDY-25-01566
NCT ID Number
Start Date (Actual)
2026-04
Last Update Posted
2026-04-02
Completion Date (Estimated)
2027-01-21
Enrollment (Estimated)
20
Study Type
Interventional
PHASE
Phase 2
Status
Not yet recruiting
Primary Purpose
Treatment
Design Allocation
Non-Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalCentral Centrifugal Cicatricial Alopecia Contains individuals diagnosed with Central Centrifugal Cicatricial Alopecia. | Deucravacitinib 12mg once-daily oral treatment for 48 weeks. |
ExperimentalFrontal Fibrosing Alopecia Contains individuals diagnosed with Frontal Fibrosing Alopecia. | Deucravacitinib 12mg once-daily oral treatment for 48 weeks. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Changes in IFNγ in CA scalp | Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Baseline to Week 24 |
Changes in CCL5 in CA scalp | Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Baseline to Week 24 |
Changes in CXCL9 in CA scalp | Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Baseline to Week 24 |
Changes in CXCL10 in CA scalp | Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Baseline to Week 24 |
Changes in TGFB1/2 in CA scalp | Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Baseline to Week 24 |
Changes in vimentin in CA scalp | Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Baseline to Week 24 |
Changes in fibronectin CA scalp | Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Baseline to Week 24 |
Changes in CTGF in CA scalp | Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Baseline to Week 24 |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Changes in IFNγ in CA scalp | Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Week 24 to Week 48 |
Changes in CCL5 in CA scalp | Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Week 24 to Week 48 |
Changes in CXCL9 in CA scalp | Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Week 24 to Week 48 |
Changes in CXCL10 in CA scalp | Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Week 24 to Week 48 |
Changes in TGFB1/2 in CA scalp | Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Week 24 to Week 48 |
Changes in vimentin in CA scalp | Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Week 24 to Week 48 |
Changes in fibronectin CA scalp | Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Week 24 to Week 48 |
Changes in CTGF in CA scalp | Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24 | Week 24 to Week 48 |
Change in The Central Hair Loss Grade (CHLG) | Change in CHLG from baseline at week 24 and week 48. The Central Hair Loss Grade is a clinical measure of severity that uses a 6 points scale (0 no central scalp hair loss, 1 - minimal central scalp hair loss, 2 - clinically evident central scalp hair loss, 3-5 advanced central scalp hair loss). | Baseline to Week 24; Baseline to Week 48 |
Change in Frontal Fibrosing Alopecia Severity Index (FFASI) | Change in FFASI from baseline at week 24 and week 48. The Frontal Fibrosis Alopecia Severity Index utilizes clinical images of the entire hairline divided into 4 sections. Score from 1-5, with higher score indicating more severity. | Baseline to Week 24; Baseline to Week 48 |
Changes in mRNA Levels of CCL5 gene expression in skin biopsies | Evaluation of how the two skin conditions (CCCA and FFA) present themselves at the microscopic level. The skin samples will be obtained via biopsies.
Changes in mRNA Levels of CCL5 gene expression in skin biopsies quantified by normalized Ct values obtained by quantitative real-time PCR assay, measured at baseline and week 24. The unit of the outcome is called Ct value and it represents the number of amplification cycles to reach a level of fluorescence in the experiment. The Ct value is directly associated to the level of expression of a gene | baseline and week 24 |
Change in Alopecia Areata Quality of Life Index (AA-QLI) | Change in Alopecia Areata Quality of Life Index (AA-QLI) in week 24 and week 48. The scores range from 0 - 30 with 0 representing no impact to quality of life and 30 representing extremely large impact. | Week 24 and Week 48 |
Change in Peak Pruritus Numerical Rating Scale (PP-NRS) | Change in Peak Pruritus Numerical Rating Scale (PP-NRS) at week 24 and week 48. The score ranges from 0 - 10 with 0 representing no itch and 10 representing worse possible itch. | Week 24 and Week 48 |
Change in hair count per cm2 | Change in number of hairs present in a 1 cm2 area between Baseline to Week 24 and Baseline to Week 48 | Baseline to Week 24; Baseline to Week 48 |
Change in sum of hair width per cm2 | Change in total hair diameter in a 2 cm2 area between Baseline to Week 24 and Baseline to Week 48 | Baseline to Week 24; Baseline to Week 48 |
Change in terminal:vellus ratio | Change in the ratio of thick pigmented long hair to fine-barely visible hairs between Baseline to Week 24 and Baseline to Week 48 | Baseline to Week 24; Baseline to Week 48 |
Change in average hairs per follicular unit | Change in hair density in a 1 cm2 area between Baseline to Week 24 and Baseline to Week 48 | Baseline to Week 24; Baseline to Week 48 |
Change in average hair width | Change in average width of each individual hair between Baseline to Week 24 and Baseline to Week 48 | Baseline to Week 24; Baseline to Week 48 |
Change in follicular units per cm2 | Change in hair density in a 1 cm2 area between Baseline to Week 24 and Baseline to Week 48 | Baseline to Week 24; Baseline to Week 48 |
Change in inter-follicular mean distance | Change in average gap between hairs using a diagnotic tool called the HairMetrix diagnostic tool that can accurately measure the interfollicular distance between baseline to Week 24 and baseline to Week 48 | Baseline to Week 24; Baseline to Week 48 |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Participants of any gender, age 18 years or older, at the time of informed consent at Screening
- Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements.
- Participant self-reports a history of at least 6 months of moderate-to-severe CA (FFA or CCCA). Diagnosis will be made clinically, and severity assessed with according to the FFASI32 ≥30 and/or CHLG ≥3.
- Participant has a negative Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at screening or within the last 12 months.
- A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP (all female participants, regardless of whether or not they have experienced/reported menarche, are considered WOCBP unless they are permanently sterile or confirmed infertile). A WOCBP who is sexually active must use a contraceptive method that is highly effective, with a failure rate of <1%, during the intervention period and for at least 28 days after the last dose of study intervention. And if a WOCBP, must have a negative highly sensitive serum pregnancy test at the screening visit and a negative urine pregnancy test at baseline performed before the first dose of study intervention.
- Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.
- Participant's cause of hair loss is indeterminable and/or they have concomitant causes of alopecia, such pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia.
- Participant has a history of CA for > 5 years since the disease onset, severe fibrosing disease, or very rapid hair loss at screening.
- Participant has a history of moderate to severe keloids on the scalp, as determined by clinical examination at screening. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.
- Other scalp disease that may impact assessment (e.g., scalp psoriasis, dermatitis, etc.).
- Participant is pregnant or breastfeeding.
- Participation in other studies involving investigational drug(s) within 4 weeks or within 5 half-lives (if known), whichever is longer, prior to study entry and/or during study participation (de novo patients only).
- Active systemic diseases that may cause hair loss (e.g., systemic lupus erythematosus, thyroiditis, systemic sclerosis, etc.).
- Any Psychiatric condition in the opinion of the investigator precludes participation in the study.
- Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (particularly thyroid disease which can be associated with hair loss), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator, the participant is inappropriate for entry into this study, or unwilling/unable to comply with STUDY PROCEDURES.
- History of thromboembolic events including DVT and PE or history of inherited coagulopathies.
- Any present malignancies or history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
- History of any lymphoproliferative disorder such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
- History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.
- History of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 0.
- Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 0 or superficial skin infection within 1 week prior to Day 0. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.
- Considered in imminent need for surgery or with elective surgery scheduled to occur during the study.
- Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology at the time of screening.
- Participant has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints, as determined by the PI.
- Have an active history of alcohol or substance abuse within 1 year prior to Day 0.
- Participant has received a live attenuated vaccine ≤ 6 weeks prior to study screening.
- History of adverse systemic or allergic reactions to components of study drug.
- Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, within 8 weeks prior to baseline visit.
- Use of other non-biologic systemic agent for CA, including, 5α-reductase inhibitors, hydroxychloroquine, or retinoids, within 4 weeks prior to baseline visit.
- Use of an intralesional corticosteroids or oral JAK inhibitor (tofacitinib, ruxolitinib, or any JAK1/TYK2 product) within 4 weeks prior to the baseline visit.
- Any previous use of a TYK2 inhibitor.
- Participant has used topical corticosteroids, and/or tacrolimus, and/or pimecrolimus or cyclosporine within 1 week before the baseline visit.
- Participant has been previously treated with biological drugs in the last 12 weeks for other indications.
- Participants previously tested with a positive or indeterminable PPD or QFT result, including participants that completed standard tuberculosis therapy.
Icahn School of Medicine at Mount SinaiBristol-Myers SquibbStudy Responsible Party
Benjamin Ungar, Principal Investigator, Assistant Professor, Icahn School of Medicine at Mount Sinai
Study Central Contact
Contact: Sharlene Martin, MPH, 2122413288, [email protected]
1 Study Locations in 1 Countries
New York
Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States
Giselle Singer, Contact, 212-241-3288, [email protected]
Benjamin Ungar, Principal Investigator